← boardnext 2026-12
CMPX
Compass Therapeuticsdistress 2/10 · well-funded / low risk$2.040%today-70% from 52w high
Oncology 2
Lead: biliary tract cancer · target PD-1
Revenue
pre-revenue
Liquidity
$195M
Runway
3.7 yrs
Shares 1y
+30%
Price & events
-67.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.2%
1D
-3.1%
1W
-1.2%
1M
-60.9%
3M
-65.5%
6M
-38.9%
1Y
+97.6%
2Y
-58.9%
5Y
-76.1%
All
Overview
- Market Cap
- $366.48M
- Volume
- 106.44K
- 52 Week Range
- $1.67 – $6.69
- Total Shares
- 180.09M
- Float Shares
- 122.69M
- Short %
- 24.65%
- % Held by Insiders
- 12.46%
- % Held by Institutions
- 93.79%
- RVOL
- 0.04x
- Beta
- 0.75
Pipeline stages · 2 programs
CTX-10726
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CTX-471, Pembrolizumab (KEYTRUDA®)PD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-01 Estimated 50% readout ~2027-02-14 | Phase 2/3 | CTX-009, Paclitaxel | Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer | — | active not recruiting |
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | CTX-8371 | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma | — | recruiting |
| 2028-04-01 Estimated 50% readout ~2028-05-01 | Phase 1 | CTX-10726 | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | — | recruiting |
| 2025-05-21 | Phase 1 | CTX-471, Pembrolizumab (KEYTRUDA®) | Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer | 100 | completed |
| 2025-05-15 | Phase 2 | CTX-009 | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer | 49 | completed |
Catalyst news & presentations · 3
- 2026-08-14earningsEarningsEarnings releaseyahoo
- todayconferencedata presentationsecondaryPhase 2/3tovecimig · Webcast to review data from COMPANION-002 studySEC 8-K
- fourth quarter of 2025readoutPhase 2/3tovecimig · Secondary endpoint data (PFS, OS, DoR) and safety to be reportedSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+318% upside) · 12 analysts
- 2026-04-28CitizensMarket Outperform
- 2026-04-28Canaccord GenuityBuy
- 2026-04-27HC Wainwright & Co.Buy
- 2026-04-27D. Boral CapitalBuy
- 2026-03-24GuggenheimBuy
- 2026-01-06D. Boral CapitalBuy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-19Enterprise value to EBIT forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
- 2026-07-18Compass Therapeutics (CMPX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
- 2026-07-17Compass Therapeutics to present Phase 2/3 tovec... - Pluang
- 2026-07-17Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 - The Manila Times
- 2026-07-17Compass Therapeutics’ COMPANION-002 Biliary Tract Cancer Study Accepted for Oral Presentation at ESMO 2026 - Quiver Quantitative
- 2026-07-17Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 - GlobeNewswire
- 2026-07-17Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 - GlobeNewswire
- 2026-07-17Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.